Mitsuhiro Machitani
Overview
Explore the profile of Mitsuhiro Machitani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
214
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Machitani M, Sakurai F, Wakabayashi K, Takayama K, Tachibana M, Mizuguchi H
Mol Ther Nucleic Acids
. 2017 Mar;
6:173-182.
PMID: 28325284
RNAi by short hairpin RNA (shRNA) is a powerful tool not only for studying gene functions in various organisms, including mammals, but also for the treatment of severe disorders. However,...
12.
Machitani M, Sakurai F, Wakabayashi K, Nakatani K, Takayama K, Tachibana M, et al.
Biol Pharm Bull
. 2017 Mar;
40(3):272-277.
PMID: 28250269
Clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9-mediated genome engineering technology is a powerful tool for generation of cells and animals with engineered mutations in their genomes. In order to introduce...
13.
Machitani M
Yakugaku Zasshi
. 2016 Nov;
136(11):1509-1515.
PMID: 27803482
The adenovirus (Ad) genome encodes two small noncoding RNAs, VA-RNA I and II, which support Ad replication by antagonizing the antiviral action associated with the Ad-induced activation of double-stranded RNA-dependent...
14.
Machitani M, Sakurai F, Wakabayashi K, Tachibana M, Fujiwara T, Mizuguchi H
Mol Cancer Ther
. 2016 Oct;
16(1):251-259.
PMID: 27760834
Oncolytic viruses have been receiving much attention as potential agents for cancer treatment. Among the various types of oncolytic viruses, the telomerase-specific replication-competent adenovirus (TRAD), which carries the tumor-specific promoter-driven...
15.
Machitani M, Sakurai F, Wakabayashi K, Tomita K, Tachibana M, Mizuguchi H
Sci Rep
. 2016 Jun;
6:27598.
PMID: 27273616
In various organisms, including nematodes and plants, RNA interference (RNAi) is a defense system against virus infection; however, it is unclear whether RNAi functions as an antivirus system in mammalian...
16.
Sakurai F, Narii N, Tomita K, Togo S, Takahashi K, Machitani M, et al.
Mol Ther Methods Clin Dev
. 2016 Mar;
3:16001.
PMID: 26966699
Circulating tumor cells (CTCs) are promising biomarkers in several cancers, and thus methods and apparatuses for their detection and quantification in the blood have been actively pursued. A novel CTC...
17.
Machitani M, Yamaguchi T, Shimizu K, Sakurai F, Katayama K, Kawabata K, et al.
Pharmaceutics
. 2013 Dec;
3(3):338-53.
PMID: 24310584
The major limitation of the clinical use of replication-incompetent adenovirus (Ad) vectors is the interference by innate immune responses, including induction of inflammatory cytokines and interferons (IFN), following in vivo...
18.
Matsui H, Sakurai F, Katayama K, Abe Y, Machitani M, Kurachi S, et al.
Biomaterials
. 2013 Mar;
34(16):4191-4201.
PMID: 23473963
A major drawback of adenovirus (Ad) vectors is their nonspecific transduction into various types of cells or tissue after in vivo application, which might lead to unexpected toxicity and tissue...
19.
Machitani M, Katayama K, Sakurai F, Matsui H, Yamaguchi T, Suzuki T, et al.
J Control Release
. 2011 Jun;
154(3):285-9.
PMID: 21703313
A major limitation of the use of adenovirus (Ad) vectors is the innate immune response, which causes inflammatory cytokine production and tissue damages. To overcome this limitation, it is necessary...
20.
Shimizu K, Sakurai F, Machitani M, Katayama K, Mizuguchi H
Mol Pharm
. 2011 Jun;
8(4):1430-5.
PMID: 21682288
Theoretically, adenovirus (Ad) genes should not be expressed following transduction with a replication-incompetent Ad vector because the E1A gene, which is essential for the expression of other viral gene, is...